Cost-Effectiveness Analysis of Implantable Collamer Lens (ICL) Surgery Versus Contact Lens-Based Correction with Backup Spectacles in Young Adults-A Norwegian Societal Perspective.
9 affiliations
- 1Center for Eye Research and Innovative Diagnostics, Department of Ophthalmology, Oslo University Hospital, 0450 Oslo, Norway.
- 2Watany Eye Hospital, Cairo 16112, Egypt.
- 3Ashraf Armia Eye Clinic, Cairo 12655, Egypt.
- 4Department of Ophthalmology, Montecchi Hospital of Suzzara, 46029 Suzzara, Mantua, Italy.
- 5Dr Nano Eye Clinic, Olivos B1636CSS, Buenos Aires, Argentina.
- 6Department of General and Pediatric Ophthalmology, Medical University of Lublin, 20-059 Lublin, Poland.
- 7Institute for Clinical Medicine, University of Oslo, 0450 Oslo, Norway.
- 8Department of Ophthalmology, University Hospital Centre, University of Split School of Medicine, 21000 Split, Croatia.
- 9UKLOnetwork, University St. Kliment Ohridski-Bitola, 7000 Bitola, North Macedonia.
Abstract
Background: Moderate-to-high refractive error generates long-term direct and indirect costs through corrective devices, complications, and productivity losses. The economic value of implantable collamer lens (ICL) surgery relative to contact lens (CL)-based correction with backup spectacles remains uncertain. Objective: To evaluate the 25-year cost-effectiveness of posterior chamber phakic ICL implantation versus CL-based correction across four refractive subgroups from a Norwegian societal perspective. Methods: A Markov cohort model followed patients aged 25-50 years with high myopia, high myopia with astigmatism, high hyperopia, or high hyperopia with astigmatism. Health states incorporated surgical complications, microbial keratitis (MK), cataract, explantation, and death. Direct medical and productivity costs were valued in 2024 Norwegian kroner (NOK), converted to United States dollars (USD), and subsequently reported in USD. Outcomes included quality-adjusted life-years (QALYs), incremental costs, incremental net monetary benefit (INMB), and cost-effectiveness probabilities at Norwegian severity-based thresholds (NOK 250,000-825,000/QALY). Deterministic and probabilistic sensitivity analyses were performed. Results: In the deterministic base case, ICL was less costly and more effective in all subgroups. Incremental QALY gains ranged from 0.049 to 0.464, and 25-year savings ranged from USD 1758 to USD 2277 per patient. At USD 27,253/QALY, INMB ranged from USD 3264 to USD 14,921. ICL produced approximately 5-6 additional cataract surgeries per 100 patients but avoided approximately 1.1-1.3 MK infections per 100 CL users and provided 0.6-0.9 additional years in the "Well" state. Cost-effectiveness probabilities ranged from 52.7% to 74.2% and were highest in the astigmatic subgroups. Utilities were the principal uncertainty drivers; the 52.7% probability observed for high hyperopia indicated limited robustness. Conclusions: Over 25 years, ICL may provide cost savings and quality-of-life gains compared with CL-based correction in appropriately selected patients. These findings depend on model assumptions and should not be interpreted as a lifetime evaluation.
Related
- Real-world effectiveness of myopia control spectacles and dual-focus contact lenses in the French myopia cohort
- Analgesic Effectiveness of Ultrasound-Guided PECS II Block in Implantable Venous Port Catheter Placement: A Retrospective Comparative Study
- Effectiveness of Contemporary Invisalign® Clear Aligners for Derotation and Deep Bite Correction of Different Degrees of Severity in Adolescents and Adults: A Retrospective Clinical Study
- A Poly‐L‐Lactic Acid Formulation for Nasolabial Fold Correction: Handling, Tolerability and Effectiveness in a Prospective Observational Study
- Cost-effectiveness of disitamab vedotin plus toripalimab versus chemotherapy alone as first-line treatment for HER2-overexpressing advanced urothelial carcinoma: a cost-effectiveness analysis from the Chinese healthcare system perspective
BibTeX
@article{hertzberg2026costeffectiveness,
title = {{Cost-Effectiveness Analysis of Implantable Collamer Lens (ICL) Surgery Versus Contact Lens-Based Correction with Backup Spectacles in Young Adults-A Norwegian Societal Perspective.}},
author = {Silvia N W Hertzberg and Ashraf Armia Balamoun and Filippo Confalonieri and Germán Roberto Bianchi and Robert Rejdak and Beata Eva Petrovski and Goran Petrovski},
journal = {Healthcare (Basel, Switzerland)},
year = {2026},
month = sep,
doi = {10.3390/healthcare14193220},
url = {https://europepmc.org/article/MED/42881659},
note = {CC BY},
}
RIS
TY - JOUR
TI - Cost-Effectiveness Analysis of Implantable Collamer Lens (ICL) Surgery Versus Contact Lens-Based Correction with Backup Spectacles in Young Adults-A Norwegian Societal Perspective.
AU - Silvia N W Hertzberg
AU - Ashraf Armia Balamoun
AU - Filippo Confalonieri
AU - Germán Roberto Bianchi
AU - Robert Rejdak
AU - Beata Eva Petrovski
AU - Goran Petrovski
PY - 2026
DA - 2026/09/30
JO - Healthcare (Basel, Switzerland)
DO - 10.3390/healthcare14193220
UR - https://europepmc.org/article/MED/42881659
AB - Background: Moderate-to-high refractive error generates long-term direct and indirect costs through corrective devices, complications, and productivity losses. The economic value of implantable collamer lens (ICL) surgery relative to contact lens (CL)-based correction with backup spectacles remains uncertain. Objective: To evaluate the 25-year cost-effectiveness of posterior chamber phakic ICL implantation versus CL-based correction across four refractive subgroups from a Norwegian societal perspective. Methods: A Markov cohort model followed patients aged 25-50 years with high myopia, high myopia with astigmatism, high hyperopia, or high hyperopia with astigmatism. Health states incorporated surgical complications, microbial keratitis (MK), cataract, explantation, and death. Direct medical and productivity costs were valued in 2024 Norwegian kroner (NOK), converted to United States dollars (USD), and subsequently reported in USD. Outcomes included quality-adjusted life-years (QALYs), incremental costs, incremental net monetary benefit (INMB), and cost-effectiveness probabilities at Norwegian severity-based thresholds (NOK 250,000-825,000/QALY). Deterministic and probabilistic sensitivity analyses were performed. Results: In the deterministic base case, ICL was less costly and more effective in all subgroups. Incremental QALY gains ranged from 0.049 to 0.464, and 25-year savings ranged from USD 1758 to USD 2277 per patient. At USD 27,253/QALY, INMB ranged from USD 3264 to USD 14,921. ICL produced approximately 5-6 additional cataract surgeries per 100 patients but avoided approximately 1.1-1.3 MK infections per 100 CL users and provided 0.6-0.9 additional years in the "Well" state. Cost-effectiveness probabilities ranged from 52.7% to 74.2% and were highest in the astigmatic subgroups. Utilities were the principal uncertainty drivers; the 52.7% probability observed for high hyperopia indicated limited robustness. Conclusions: Over 25 years, ICL may provide cost savings and quality-of-life gains compared with CL-based correction in appropriately selected patients. These findings depend on model assumptions and should not be interpreted as a lifetime evaluation.
SN - 2227-9032
ER -